Biomarkers for PD: How can we approach complexity?

Neurology

Volumn 80, Issue 7, 2013, Pages 608-609

  Berg, Daniela ^a   Bandmann, Oliver ^b  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

DISEASE COURSE; EDITORIAL; GENE; GENE MUTATION; HUMAN; HYPOSMIA; LRRK2 GENE; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMELLING; SUBSTANTIA NIGRA; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MUTATION; NOTE; SMELLING DISORDER;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUTATION; OLFACTION DISORDERS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84875821080     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182825184     Document Type: Editorial

References (11)

1. Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012;27:617-626.
2. Sierra M, Sánchez-Juan P, Martínez-Rodríguez MI, et al. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease. Neurology 2013; 80:621-626.
3. Berg D, Seppi K, Behnke S, et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 2011;68:932-937.
4. Seibyl J, Russell D, Jennings D, Marek K. Neuroimaging over the course of Parkinson's disease: from early detection of the at-risk patient to improving pharmacotherapy of later-stage disease. Semin Nucl Med 2012;42:406-414.
5. Brockmann K, Groger A, Di Santo A, et al. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011;26:2335-2342.
6. Bruggemann N, Hagenah J, Stanley K, et al. Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. Mov Disord 2011;26:885-888.
7. Hagenah JM, Becker B, Bruggemann N, et al. Transcranial sonography findings in a large family with homozygous and heterozygous PINK1 mutations. J Neurol Neurosurg Psychiatry 2008;79:1071-1074.
8. Ruprecht-Dorfler P, Berg D, Tucha O, et al. Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. Neuroimage 2003;18:416-422.
9. Mortiboys H, Johansen KK, Aasly JO, Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 2010;75:2017-2020.
10. Gröger A, Berg D. Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies. J Neural Transm 2012;119:1523-1528.
11. Berg D, Marek K, Ross GW, Poewe W. Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. Mov Disord 2012;27:656-665.